Latest Breaking News On - Avidity bioscience - Page 1 : comparemela.com

Avidity Up 33% on Rare Muscle Disease Study Results - Arcutis Biotherapeutics (NASDAQ:ARQT), Heron Therapeutics (NASDAQ:HRTX)

Avidity Biosciences (NASDAQ: RNA) announced encouraging initial data from the phase I/II FORTITUDE study evaluating two doses of delpacibart braxlosiran (del-brax, or formerly AOC 1020) in facioscapulohumeral muscular dystrophy (FSHD), a rare genetic disease of the muscles.

We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the.

KalVista Pharmaceuticals (NASDAQ:KALV) & Avidity Biosciences (NASDAQ:RNA) Financial Review

KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) and Avidity Biosciences (NASDAQ:RNA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends. Earnings & Valuation This table compares KalVista […]

Chardan Capital Weighs in on Avidity Biosciences, Inc.'s FY2023 Earnings (NASDAQ:RNA)

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Rating) – Chardan Capital dropped their FY2023 EPS estimates for Avidity Biosciences in a report released on Wednesday, May 10th. Chardan Capital analyst K. Nakae now forecasts that the biotechnology company will earn ($2.94) per share for the year, down from their prior forecast of ($2.90). Chardan Capital currently […]

FDA gives orphan drug status to Avidity's rare muscular dystrophy treatment